Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection.

Hariyanto, Timotius Ivan; Prasetya, Ignatius Bima; Kurniawan, Andree

Hariyanto, Timotius Ivan; Prasetya, Ignatius Bima; Kurniawan, Andree.

Hariyanto TI; Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman street, Karawaci, Tangerang 15811, Indonesia.
Prasetya IB; Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman street, Karawaci, Tangerang 15811, Indonesia.
Kurniawan A; Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman street, Karawaci, Tangerang 15811, Indonesia. Electronic address: andree.kurniawan@uph.edu.

Dig Liver Dis ; 52(12): 1410-1412, 2020 12.

Article in English | MEDLINE | ID: covidwho-816422

Subject(s)

COVID-19/mortality; Proton Pump Inhibitors/therapeutic use; COVID-19/physiopathology; Hospital Mortality; Humans; Risk Factors; Severity of Illness Index

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Proton Pump Inhibitors / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Dig Liver Dis Journal subject: Gastroenterology Year: 2020 Document Type: Article Affiliation country: J.dld.2020.10.001

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google